Advanced IBD Endoscopy & Dysplasia Surveillance
Module Overview
Chromoendoscopy, high-definition white-light endoscopy for dysplasia surveillance, stricture dilation, and post-surgical endoscopy including pouch assessment.
Benchmark Source: ECCO Endoscopy Module + UC San Diego Procedural Track
Learning Objectives
Perform dye-based and virtual chromoendoscopy for dysplasia surveillance
Apply SCENIC consensus recommendations for dysplasia management
Perform endoscopic balloon dilation for IBD strictures
Assess ileal pouch anatomy and diagnose pouchitis
Teaching Sessions
Chromoendoscopy & Advanced Imaging for Dysplasia Detection
High-definition white-light endoscopy (HD-WLE), dye-based and virtual chromoendoscopy (NBI, BLI, LCI), SCENIC consensus, and the approach to dysplasia surveillance in UC and colonic Crohn's.
1Dysplasia Risk & Surveillance Intervals
Patients with extensive UC or Crohn's colitis involving >1/3 of colon have 2–3× population risk of colorectal cancer (CRC); risk rises with disease duration (begin surveillance 8 years after symptom onset), extent, persistent inflammation, PSC (start at diagnosis, annually), family history of CRC, and past dysplasia. BSG/ACG/ECCO stratify patients into low, intermediate, and high risk: high risk (PSC, prior dysplasia, stricture, extensive uncontrolled disease, first-degree relative <50) → annual colonoscopy; intermediate (mild-moderate active disease, post-inflammatory polyps, family history any age) → 2–3 years; low (quiescent disease, no other risk factors) → 5 years. Saudi cohorts show rising IBD-CRC incidence with longer disease duration; many patients present at diagnosis with extensive disease, warranting earlier surveillance. Document extent at each colonoscopy (maximum extent ever reached), not current inflammation level.
PSC-UC patients carry a cumulative 30-year CRC risk approaching 30%—these patients need annual colonoscopy starting at PSC diagnosis regardless of IBD duration, with aggressive chromoendoscopy and biopsy of any subtle lesion. Do not delay surveillance even if disease is clinically quiescent.
- Surveillance begins 8 years after UC/colitis symptom onset (not diagnosis)
- PSC: annual colonoscopy from PSC diagnosis, lifelong
- Intervals: high-risk 1y, intermediate 2–3y, low 5y
- Document maximum historical extent, not current inflammation
- Saudi IBD-CRC incidence rising; counsel about individual cumulative risk
2HD-WLE vs Chromoendoscopy vs Virtual Chromoendoscopy
SCENIC 2015 consensus established dye-based chromoendoscopy (DCE) with methylene blue 0.1% or indigo carmine 0.03–0.4% as preferred technique when HD-WLE alone is used; with modern HD systems, SCENIC and subsequent meta-analyses show DCE and HD-WLE with targeted biopsies have similar dysplasia detection when lesion-focused technique is applied. ASGE PIVI requires a dysplasia detection rate ≥33% improvement over random biopsies. Virtual chromoendoscopy (narrow-band imaging NBI, blue-light imaging BLI, linked-color imaging LCI) uses wavelength-filtered light to enhance mucosal and vascular patterns without dye; recent RCTs show NBI non-inferior to DCE for dysplasia detection with shorter procedure time. LCI (Fujifilm) enhances red-to-white contrast and may improve lesion visibility in inflamed mucosa. Technique matters more than modality: meticulous bowel preparation (Boston score ≥8), slow withdrawal (≥6 min per segment), segmental insufflation, and lesion-directed biopsies. Random 4-quadrant biopsies every 10 cm (33 biopsies) are no longer recommended unless DCE/VCE unavailable or mucosa obscured; EGD findings are unaffected by this change.
Chromoendoscopy requires technique more than equipment: spray dye via a dedicated catheter or flushing pump in segments (cecum first, then withdraw), wait 30 seconds, then inspect with slow withdrawal. Poor bowel preparation is the #1 reason dysplasia is missed—reschedule if Boston score <6 in right colon. SCENIC terminology: describe lesions as "visible" (polypoid vs non-polypoid, with/without surface pattern) rather than "DALM" or "ALM".
- DCE and HD-WLE with targeted biopsies have equivalent dysplasia yield
- VCE (NBI/BLI/LCI) non-inferior to DCE with faster procedures
- Random 4-quadrant biopsies no longer standard of care
- Boston score ≥8 required; reschedule if <6 in right colon
- Adopt SCENIC terminology (visible/invisible, polypoid/non-polypoid)
3Lesion Characterization: Paris, Kudo, NICE, JNET
Paris classification describes morphology: type 0-Ip pedunculated, 0-Is sessile, 0-IIa slightly elevated (<2.5 mm), 0-IIb flat, 0-IIc slightly depressed, 0-III excavated. Non-polypoid lesions (0-II) have higher dysplasia risk per unit and are often missed. Kudo pit pattern uses DCE/magnification to classify: types I-II (non-neoplastic), IIIL/IIIs/IV (adenoma), Vi/Vn (high-grade dysplasia/cancer). NICE classification (for NBI, non-magnifying): type 1 (hyperplastic: light color, no vessels), type 2 (adenoma: brown with clear vessels/tubular pattern), type 3 (deep cancer: dark with distorted/absent pattern). JNET (Japan NBI Expert Team) refines this with magnification: 1 (hyperplastic/SSL), 2A (low-grade adenoma), 2B (high-grade/superficial SM invasion), 3 (deep SM invasion). In IBD, flat dysplasia within inflamed mucosa may lack typical adenomatous vascular patterns; apply NICE/JNET cautiously and biopsy anything suspicious. Always photograph lesions with white light, chromoendoscopy, and NBI for MDT review.
Train your eyes on Paris/NICE/JNET by reviewing atlases regularly. In a Saudi tertiary center, >20% of IBD dysplasia is subtle non-polypoid (Paris 0-IIa or 0-IIb). Always use a cap on the colonoscope—it straightens folds, reduces blind spots in the right colon, and helps visualize lesions on proximal sides of folds where up to 15% of right-sided lesions hide.
- Paris 0-II (non-polypoid) easy to miss and higher dysplasia risk
- NICE type 2 = adenoma; type 3 = deep cancer (defer polypectomy, refer)
- Photograph lesions in WLE + DCE + NBI for MDT correlation
- Use a cap for improved fold visualization and right-sided yield
- >20% of IBD dysplasia is subtle flat/depressed in Saudi tertiary data
4Endoscopic Resection Decision-Making in IBD
SCENIC permits endoscopic resection of endoscopically visible, completely resectable dysplastic lesions in IBD with continued surveillance instead of colectomy. Key criteria for endoscopic management: (1) clear margins achievable, (2) no features of deep invasion (no NICE 3, no JNET 3, no non-lifting sign, no ulceration, no fixed lesion), (3) no flat dysplasia in surrounding mucosa on DCE, (4) no invisible dysplasia on random biopsies elsewhere. Lesion type dictates technique: small polypoid (<10 mm) → standard polypectomy; larger polypoid → EMR; flat/non-polypoid → ESD for en-bloc R0 resection preferred over piecemeal EMR (which has higher recurrence risk in IBD). Tattoo 3 cm distal to lesion with SPOT or India ink (three quadrants) for relocalization; mark borders with APC if biopsies taken. After resection: 3–6 month site inspection with DCE, 12 months for further surveillance. Indications for colectomy: invisible high-grade dysplasia on multiple biopsies, multifocal low-grade dysplasia (>2 sites), dysplasia adjacent to a non-resectable lesion, patient factors (PSC with recurrent dysplasia, poor surveillance compliance).
ESD in IBD is technically challenging because submucosal fibrosis from chronic inflammation reduces lift—use viscous solutions (hyaluronic acid, SucceessLifter, sodium alginate) rather than saline. In Saudi centers with ESD capability (KFSHRC, KAMC, KFMC, KFSH Dammam), refer complex IBD dysplasia to expert centers rather than attempting piecemeal EMR that may compromise oncologic outcomes.
- Visible resectable dysplasia → endoscopic resection + surveillance (not colectomy)
- ESD preferred for flat/non-polypoid >20 mm to achieve en-bloc R0
- Tattoo 3 cm distal for relocalization; mark borders pre-resection
- Refer complex IBD dysplasia to expert ESD centers (Saudi tertiary)
- Invisible HGD, multifocal LGD, or adjacent unresectable lesion → colectomy
5Artificial Intelligence (CADe/CADx) in IBD Surveillance
Computer-aided detection (CADe) using deep learning has been FDA-approved for colonoscopy (GI Genius, EndoBRAIN, EndoAID) and improves adenoma detection rate in average-risk screening by ~10–15 percentage points. IBD-specific data emerging: early prospective studies show CADe detects subtle flat lesions at rates equal to or exceeding expert endoscopists, particularly for non-polypoid dysplasia. Limitations in IBD: chronic inflammation, pseudopolyps, scarring, and prior surgery create false positives and reduce specificity; current AI models were trained mainly on non-IBD datasets. CADx (computer-aided diagnosis) assists with optical lesion characterization (NICE/JNET) but lacks IBD-specific validation. Saudi clinical uptake: AI systems available at KFSHRC, KFMC, and several private centers. Use AI as adjunct, not replacement—it prompts "second look" at flagged areas but final diagnosis remains the endoscopist's. Document AI use in the report (model, version, rate of flags accepted/rejected).
AI in IBD is not yet a substitute for chromoendoscopy or HD-WLE with careful technique—use it as a safety net. In pseudopolyp-rich colons, toggle AI off during visualization of known pseudopolyps to avoid alert fatigue, then toggle back on in uninvolved-appearing segments.
- CADe FDA-approved and improves polyp detection ~10–15% in non-IBD
- Emerging IBD data show promise for subtle flat lesion detection
- Pseudopolyps and scarring reduce AI specificity in IBD
- Use AI as adjunct; document model/version/accept-reject rate
- Available in Saudi tertiary centers; not yet standard of care in IBD
- Surveillance begins 8 years after symptom onset; annual for PSC-UC regardless of duration
- DCE and HD-WLE with targeted biopsies are equivalent when technique is meticulous
- Random 4-quadrant biopsies are no longer required if DCE/VCE performed
- Visible resectable dysplasia managed endoscopically, not by colectomy
- AI is adjunctive in IBD—no substitute for chromoendoscopy and expert technique
Hands-On Chromoendoscopy Workshop (Simulator + Live)
Practical session on chromoendoscopy preparation, dye delivery, lesion characterization, and biopsy technique using phantom colons and patient cases.
1Station 1: Dye Preparation & Delivery Technique
Indigo carmine 0.03% prepared by diluting 5 mL of 0.8% stock in 100 mL saline; methylene blue 0.1% diluted from 10 mL 1% stock in 90 mL saline. Delivery options: (1) dedicated spray catheter (PW-205V or similar) via working channel—optimal for segmental coating; (2) flushing pump through auxiliary water channel—faster but less targeted; (3) direct syringe injection—rarely adequate. Volume: 100–120 mL total for full colon, applied in segments during withdrawal. Technique: insert catheter, spray proximal to scope tip while gradually withdrawing over 15–20 cm, rotate scope to coat all quadrants, suction excess pooled dye, wait 30 seconds for absorption, then inspect. Avoid over-insufflation (flattens mucosa, obscures pit patterns). Document total dye volume and any adverse reactions (methylene blue rarely causes hemolysis in G6PD deficiency—important in Saudi population where G6PD deficiency prevalence is 2–5%).
If a patient has known G6PD deficiency, use indigo carmine instead of methylene blue. In Saudi Arabia, always ask about neonatal jaundice history or favism (fava bean sensitivity) as screening—clinically proven G6PD deficiency warrants avoiding methylene blue.
- Indigo carmine 0.03% or methylene blue 0.1%; prepare fresh per case
- Dedicated spray catheter is the gold standard for segmental delivery
- 100–120 mL total; 15–20 cm at a time; wait 30s post-spray
- Screen for G6PD deficiency before methylene blue (Saudi prevalence 2–5%)
- Document dye volume, method, and any reaction in report
2Station 2: Lesion Detection on Phantom Colons
Participants practice on silicone phantom colons embedded with simulated lesions (Paris 0-Is, 0-IIa, 0-IIb, 0-IIc) and pseudopolyps using both HD-WLE and DCE. Structured learning: first pass with white light, document time and lesions found; second pass with indigo carmine spray, re-document. Compare detection rates. Key skills: (1) slow withdrawal (aim ≥6 min per segment, set timer), (2) systematic rotational scanning, (3) fold manipulation by pushing and retroflexion in rectum and sigmoid, (4) cap-assisted inspection of blind spots (ileocecal valve proximal side, hepatic flexure medial wall, splenic flexure). Instructor provides real-time feedback on technique. Trainees should achieve ≥90% lesion detection with DCE before proceeding to live cases. Self-assessment checklist includes: time per segment, dye technique quality, lesion characterization accuracy using Paris/NICE, and biopsy precision.
Set a timer—endoscopists consistently underestimate withdrawal time. Trainees who feel they withdrew "slowly" often complete a segment in <3 min. Use the endoscopy tower clock or a phone stopwatch; 6 min per segment is the minimum target.
- Practice WLE then DCE on same phantom; document detection deltas
- Slow withdrawal ≥6 min/segment; use a visible timer
- Systematic rotation + fold manipulation + cap assistance
- Target ≥90% phantom detection before live cases
- Self-assessment checklist: time, technique, characterization, biopsy
3Station 3: Virtual Chromoendoscopy (NBI/BLI/LCI) Live
Under supervision, trainees perform VCE-assisted surveillance on 2–3 consented IBD patients. Focus on pattern recognition: NBI enhances vascular patterns and surface architecture; BLI (Fujinon) similar but with different wavelengths; LCI enhances red-white color contrast for lesion visibility in inflamed mucosa. Trainees photograph any suspicious area in WLE + VCE + (optional DCE), then apply NICE classification: type 1 (hyperplastic: light color, no vessels), type 2 (adenoma/dysplasia: brown, clear vessels), type 3 (deep cancer: dark, distorted). Document lesions with accurate location (distance from anus or anatomic landmark), size (open-biopsy forceps = 8 mm, use as reference), Paris morphology, NICE/JNET, and biopsy or resection plan. Review images together post-procedure.
Use "dual focus" or near-focus mode on VCE-capable scopes when available for magnified lesion characterization without switching scopes. Biopsy forceps width (8 mm when fully open) is the most reliable in-scope size reference—train yourself to compare lesion diameter to open forceps in every image.
- Supervised VCE on 2–3 IBD patients with informed consent
- Photograph suspicious areas in WLE + VCE for pattern analysis
- Apply NICE/JNET classifications; document Paris morphology
- Use open biopsy forceps (8 mm) as in-scope size reference
- Dual-focus mode enables magnification without scope change
4Station 4: Targeted Biopsy & Tattooing
Biopsy technique: use jumbo cold forceps (2.8 mm working channel minimum, e.g., Radial Jaw 4 Jumbo) for adequate tissue yield; grasp lesion margin tangentially rather than straight-on; take 2–4 biopsies per lesion from different quadrants; label separately (e.g., "transverse colon visible lesion biopsy 1 of 3"). For flat lesions, consider biopsy + forceps elevation to see the substrate or proceed to EMR in one session if fully resectable. Always biopsy mucosa 2 cm on either side of a visible lesion to assess for surrounding invisible dysplasia; take 2 biopsies each side. Tattoo: inject 0.5–1 mL SPOT (sterile India ink, Kenji) or clear carbon-based commercial tattoo 3 cm distal to the lesion in 3 quadrants, creating a visible mark for surgical or follow-up localization; avoid tattooing the lesion itself or within 1 cm (may obscure margins at follow-up). Document all actions in the report with photos: lesion image, biopsy site image, tattoo site image.
India ink from non-sterile sources can cause sterile abscess—use only commercial preparations (SPOT, EZ Mark) or sterilized India ink. For small lesions, take a biopsy before EMR to confirm dysplasia histologically before committing to resection, especially in difficult locations (appendiceal orifice, ileocecal valve).
- Jumbo cold forceps; tangential grasp; 2–4 biopsies per lesion
- Biopsy surrounding mucosa 2 cm on each side of lesion
- Tattoo 3 cm distal in 3 quadrants; use commercial SPOT or sterile ink
- Never tattoo within 1 cm of lesion or in the lesion itself
- Photograph lesion, biopsy site, and tattoo site in report
- Prepare dye fresh; screen for G6PD deficiency before methylene blue in Saudi patients
- Meticulous withdrawal time ≥6 min/segment with timer is non-negotiable
- Apply NICE/JNET in real time; photograph lesions in WLE + VCE + DCE
- Biopsy with jumbo cold forceps tangentially; sample surrounding mucosa
- Tattoo with commercial SPOT or sterile ink 3 cm distal in 3 quadrants
Stricture Assessment & Endoscopic Balloon Dilation
Principles of IBD stricture evaluation (inflammatory vs fibrotic), patient selection for endoscopic balloon dilation (EBD), technique, outcomes, and when to refer for surgery.
1Inflammatory vs Fibrotic Strictures: Imaging + Endoscopic Clues
IBD strictures (common in Crohn's, occasionally UC) have mixed inflammatory and fibrotic components; the relative proportion dictates therapy. Inflammatory predominant strictures respond to medical escalation (corticosteroids, biologics, small molecules). Fibrotic strictures require endoscopic dilation or surgical resection/strictureplasty. Differentiation on MRE: inflammatory strictures show mural thickening with hyperenhancement on post-contrast T1, hyperintensity on T2 fat-saturated sequences, diffusion restriction (low ADC), and comb sign. Fibrotic strictures show mural thickening with low-to-intermediate T2 signal, reduced hyperenhancement, and no diffusion restriction. Often mixed—newer techniques (MT-MRE, DCE-MRI, ultrasound strain elastography) quantify fibrosis. Endoscopically: active ulcers + edema + erythema suggest inflammatory; smooth, pale, rigid mucosa with cecal-ward passage resistance suggest fibrotic. Clinical context: recent flare → likely inflammatory; years-long stable symptoms → likely fibrotic. In Saudi population where TB remains endemic, rule out intestinal TB as cause of ileocecal stricture (QuantiFERON-TB, biopsy histology for granulomas + AFB stain).
A stricture that "lets a pediatric colonoscope through but not an adult scope" is often passable and can be reassessed after 3 months of optimized medical therapy if inflammatory features predominate. Don't rush to dilation if inflammation may resolve. Conversely, symptomatic fibrotic strictures will not respond to biologics.
- Mixed inflammatory + fibrotic common; proportion dictates therapy
- MRE: T2 signal, diffusion, enhancement differentiate components
- Inflammatory → medical escalation; fibrotic → EBD or surgery
- Exclude intestinal TB in Saudi patients with ileocecal strictures
- Pediatric scope passage with active inflammation → try medical first
2Patient Selection & Pre-EBD Assessment
Ideal EBD candidates: short (<4–5 cm), straight, accessible (primary anastomotic, ileocolonic anastomotic, or primary in descending colon/rectum), non-ulcerated, no associated fistula or abscess. CREOLE and other cohorts show 1-year surgery-free rates ~70–80% after EBD for selected anastomotic strictures. Relative contraindications: ulcerated strictures (higher perforation risk), angulated/tortuous strictures (technical failure), strictures >5 cm (limited sustained patency), prestenotic dilation with fecal stasis (risk of fecal contamination), or associated penetrating disease (abscess/fistula). Absolute: free perforation, active deep ulcer within stricture, suspected malignancy (biopsy first), inability to obtain informed consent about 3–4% perforation risk. Pre-procedure: cross-sectional imaging (MRE or CTE) within 3 months; rule out abscess and penetrating disease; hold anti-thrombotic agents per ASGE guidelines; IV access; informed consent explicitly documenting perforation risk, bleeding, failure to cross, and need for surgery.
Always obtain cross-sectional imaging before EBD. A stricture with an associated abscess (seen on MRE but not endoscopically) is a contraindication—dilation can convert a contained phlegmon into sepsis. If MRE shows a 2-cm non-draining abscess, drain percutaneously or surgically first, then reassess.
- Ideal: ≤5 cm, straight, accessible, non-ulcerated, no fistula/abscess
- MRE/CTE within 3 months to exclude penetrating disease
- Pre-procedure consent must document 3–4% perforation risk
- Biopsy suspicious strictures for malignancy before dilation
- Anastomotic strictures have best EBD outcomes (~80% 1-year surgery-free)
3EBD Technique: Balloons, Insufflation, Steroids
Equipment: through-the-scope (TTS) controlled-radial-expansion (CRE) balloons; typical sizes for ileocolonic strictures 12-13.5-15 mm (Boston CRE), 15-16.5-18 mm, 18-19-20 mm. Start at 12-15 mm for initial dilation in unfractured strictures; avoid exceeding 20 mm in a single session to reduce perforation risk. Technique: (1) advance scope to stricture; if cannot pass, use a guidewire under fluoroscopy to position balloon across; (2) pass balloon through channel, position centered across stricture; (3) inflate with water (saline can be substituted) to pre-set pressures using inflation device with gauge; (4) hold each inflation for 30–60 seconds; (5) deflate, inspect mucosa for tears/bleeding, then inflate to next increment. Stop if: significant bleeding, mucosal tear extending full depth, patient pain disproportionate, inability to reach target diameter. Intralesional corticosteroids (triamcinolone 40–80 mg per site) may reduce restenosis in anastomotic strictures—evidence is mixed. Post-procedure: observation 1–2 hours, diet advance as tolerated, schedule follow-up at 3 months with clinical assessment.
Inflate slowly with a gauge device—never use "blind" syringe inflation. Stop at the first diameter that achieves good effect (scope passage) rather than always escalating to max balloon size. Over-dilation does not improve outcomes and increases perforation risk.
- CRE TTS balloons; start 12–15 mm; max 20 mm per session
- Hold each inflation 30–60s; inspect mucosa between increments
- Guidewire under fluoroscopy for blind or tortuous strictures
- Consider intralesional triamcinolone 40–80 mg for anastomotic
- Follow up 3 months; repeat EBD pragmatic vs refer to surgery
4Outcomes, Complications, and Surgical Referral Criteria
Technical success (achieving target diameter): 85–95% for accessible strictures. Clinical response (symptom improvement): 70–80% at 1 year. Cumulative rates of surgery after EBD: ~25% at 1 year, ~40% at 3 years, ~50% at 5 years (varies by stricture type and medical optimization). Repeat dilations are common (mean 2 per patient over 5 years). Complications: perforation 2–4% (higher with ulcerated strictures, balloon >20 mm, or Crohn's primary strictures vs anastomotic), bleeding 1–2%, aspiration (with sedation). Perforation management: contained microperforation in a stable patient may be managed conservatively (NPO, IV antibiotics, close surgical consultation); frank perforation requires urgent surgery. Refer for surgery when: (1) stricture length >5 cm, (2) multiple adjacent strictures, (3) associated fistula/abscess not amenable to percutaneous drainage + medical therapy, (4) refractory despite 2–3 EBD sessions within 12 months, (5) suspicion of malignancy, (6) patient preference. Saudi MDT principle: stricture discussions involve GI + colorectal surgery + radiology to align on operative vs endoscopic approach.
Document every EBD in a patient's cumulative record: stricture location, length, balloon sizes, complications, follow-up symptoms. Use a standard template to enable QI review and informed discussions at MDT. Three failed EBDs in 12 months should trigger automatic surgical referral.
- Technical success 85–95%; 1-year surgery-free 70–80%
- Perforation 2–4%; higher with ulcers, >20 mm, primary strictures
- Micro-perforation: NPO + IV Abx + surgical consult; frank perforation: OR
- Surgical referral: >5 cm, multi-focal, fistula, refractory, malignancy
- MDT (GI + surgery + radiology) for all complex stricture decisions
- Differentiate inflammatory vs fibrotic strictures before deciding therapy
- Rule out TB in Saudi patients with ileocecal strictures (QFT + biopsy)
- EBD best for short (<5 cm), accessible, non-ulcerated anastomotic strictures
- Start 12–15 mm, max 20 mm per session; use gauge inflation, not blind
- Perforation 2–4%; document every EBD; 3 failures/12 mo → surgery referral
Dysplasia Management — Case-Based MDT Workshop
Interactive case series on dysplasia decision-making: LGD vs HGD, visible vs invisible, management algorithms, and second-opinion pathology.
1Case 1: Visible Polypoid LGD in Left-Sided UC
A 47-year-old Saudi male with left-sided UC for 11 years, in remission on mesalamine, presents for surveillance DCE colonoscopy. A 12 mm pedunculated polyp (Paris 0-Ip) is seen in the sigmoid; NICE type 2 pattern; no surrounding flat mucosal abnormality; no other lesions; random biopsies negative for invisible dysplasia elsewhere. Polyp is snare-resected en bloc with clean margins. Pathology: tubular adenoma with low-grade dysplasia, complete resection, no submucosal invasion. Discussion: per SCENIC, this is a completely resected visible polypoid LGD in the context of IBD with no adjacent or distant dysplasia—management is continued surveillance, not colectomy. Interval: next colonoscopy at 6 months to inspect resection site with DCE, then 1 year, then return to risk-stratified interval (likely annual given prior dysplasia). Counseling: patient informed of residual CRC risk and importance of adherence. Decision documented in MDT note.
This is a key SCENIC take-home case: don't refer for colectomy. Document the SCENIC criteria met (visible, resected en bloc, clean margins, no surrounding or distant dysplasia). Share this with your pathology colleagues so they report dysplasia in a SCENIC-concordant way (visible vs invisible rather than DALM/ALM).
- Visible polypoid LGD, resected en bloc, no surrounding/distant dysplasia
- Management: continued surveillance, not colectomy (SCENIC)
- Follow-up 6 months (site), 1 year, then risk-stratified
- Document SCENIC criteria explicitly in report and MDT note
- Educate pathology team to use SCENIC terminology
2Case 2: Invisible Multifocal LGD on Random Biopsies
A 55-year-old female with pancolitis for 17 years, well controlled, presents for surveillance. DCE colonoscopy is visually normal with mild chronic changes; targeted biopsies from a questionable 3 mm area show only chronic inflammation. However, random 4-quadrant biopsies taken from ascending, transverse, and sigmoid colon (older-protocol institutional policy) show LGD in 3 of 4 biopsies from transverse colon and 2 of 4 from sigmoid. Slides are sent for expert GI pathology second opinion: confirms multifocal LGD in two segments. Discussion: invisible multifocal LGD on expert-confirmed pathology has significant progression risk to HGD/CRC (~15–25% over 5 years in historical series) and is an indication for colectomy or intensive surveillance at 3–6 months with expert endoscopy. Given patient age and two separate segment involvement, MDT recommends total proctocolectomy with IPAA; patient accepts after shared decision conversation. Alternative for patients declining surgery: intensive surveillance with DCE/VCE every 3–6 months at an expert center with pre-emptive planning for colectomy if any progression.
Always obtain expert GI pathology second opinion for dysplasia before surgical referral—interobserver variability in dysplasia grading is substantial. Saudi tertiary centers with dedicated GI pathologists (KFSHRC, KAUH, KAMC, KFMC) can provide second-opinion services; build referral relationships before you need them.
- Invisible multifocal LGD: 15–25% progression to HGD/CRC over 5 years
- Indication for colectomy vs intensive 3–6 month surveillance
- Obtain expert GI pathology second opinion before surgery
- Saudi tertiary centers provide GI pathology consultation
- Shared decision-making on colectomy vs surveillance is essential
3Case 3: Non-Polypoid HGD with Adjacent Flat Dysplasia
A 62-year-old male with pancolitis and PSC for 20 years. DCE shows a 2.5 cm slightly elevated (Paris 0-IIa) lesion in the ascending colon with NICE type 2 pattern transitioning to irregular vessels at one margin (suggestive of HGD), with visible ill-defined flat dysplasia extending beyond the lesion margin over an additional 3 cm. Biopsies: central lesion HGD, adjacent flat mucosa LGD. Discussion: non-polypoid HGD with contiguous and surrounding flat dysplasia is not amenable to endoscopic resection with clean margins. PSC adds additional CRC risk. MDT consensus: proctocolectomy with IPAA (standard for this high-risk scenario). If PSC is advanced with limited liver reserve, a two-stage approach may be needed; transplant hepatology consultation prior to major surgery. Patient referred to expert colorectal surgery center (KFSHRC) for preoperative assessment including stoma marking and preoperative education.
PSC-UC with dysplasia represents highest CRC risk—essentially all such patients warrant surgery unless very short life expectancy from another cause. Coordinate with hepatology before colectomy in advanced PSC; portal hypertension and coagulopathy complicate surgery. Pouch function in PSC is typically good but risk of pouchitis is higher.
- Non-polypoid HGD with surrounding flat dysplasia → proctocolectomy
- PSC-UC with dysplasia: essentially always an indication for surgery
- Coordinate with hepatology in advanced PSC before major surgery
- Refer to expert colorectal surgery center with IPAA experience
- Preoperative stoma marking and patient education improve outcomes
4Case 4: Indefinite for Dysplasia (IND) — Navigating Uncertainty
A 38-year-old Saudi woman with 9-year pancolitis reactivated 4 months prior, now in clinical remission on infliximab. Surveillance DCE shows mild residual inflammation; targeted biopsies from a faintly irregular area return "indefinite for dysplasia" (IND) per the WHO/Riddell classification. IND signifies architectural or cytologic atypia that cannot be confidently called reactive inflammation vs dysplasia—often due to active inflammation, regenerative changes, or sampling limitations. Management: (1) expert second-opinion pathology is the first step, (2) optimize medical therapy to achieve histologic remission, (3) repeat colonoscopy with DCE in 3–6 months once inflammation is resolved, (4) if IND persists on expert pathology despite remission, escalate to more intensive surveillance or endoscopic resection of the area for complete histologic assessment. Do not proceed to colectomy based on IND alone. In Saudi context, document medication adherence and access concerns that may have contributed to reactivation—ensure sustained biologic therapy before repeating assessment.
IND is a pathologist's signal of uncertainty, not a diagnosis. The right response is to reduce uncertainty: expert second opinion, remission induction, repeat sampling. Many IND lesions are reclassified as reactive after inflammation resolves. Patient and family reassurance is important—IND is not cancer.
- IND ≠ dysplasia; it signals diagnostic uncertainty
- Steps: expert pathology, induce histologic remission, repeat in 3–6 months
- Do not colectomize on IND alone without persistent expert-confirmed pathology
- Many IND cases reclassify as reactive after inflammation resolves
- Document adherence barriers in Saudi context; ensure biologic continuity
- Visible resected LGD with clean margins → surveillance, not colectomy
- Invisible multifocal LGD with expert confirmation → colectomy vs intensive surveillance
- Non-polypoid HGD with surrounding flat dysplasia → proctocolectomy
- PSC-UC with dysplasia warrants surgical referral; coordinate with hepatology
- IND is uncertainty: second opinion, remission, repeat sampling — never colectomy alone
IBD Endoscopic Video Atlas & Structured Reporting
Review of high-yield IBD endoscopic findings via video, standardized scoring (Mayo, UCEIS, SES-CD, Rutgeerts), and structured reporting templates for fellowship practice.
1Video Atlas: UC Appearances Across Severity
High-yield videos reviewed: (1) Mayo 0 (normal/pale mucosa, clear vascular pattern) vs quiescent UC (decreased vascular pattern); (2) Mayo 1 (erythema, mild granularity, preserved vessels); (3) Mayo 2 (marked erythema, absent vessels, friability, erosions); (4) Mayo 3 (spontaneous bleeding, ulcers, friability at touch). Pseudopolyps in chronic UC: multiple tag-like polypoid projections from regenerating mucosa, typically distributed in formerly ulcerated segments. Chronic quiescent mucosa: loss of haustration ("lead-pipe" colon), atrophic appearance, rectal narrowing. Backwash ileitis: mild erythema and aphthae in terminal ileum in pancolitis, usually <5 cm from ileocecal valve. Indeterminate colitis features: patchy disease, deep ulcers with surrounding normal mucosa, anal involvement—prompts reconsideration of Crohn's. Post-colectomy surveillance: pouchitis (Mayo pouch score 0–3 for each of 4 zones), cuff inflammation, inlet stricture.
A photo-rich video reference library (institutional or personal) accelerates Mayo/UCEIS scoring consistency. Score blinded, then compare to senior interpretation—your scores should align within 1 point on UCEIS to demonstrate competency before independent reporting.
- Mayo 0–3 scale plus pseudopolyps, lead-pipe, backwash ileitis
- Pouchitis scoring (Mayo pouch 0–3) across 4 zones post-colectomy
- Indeterminate features prompt reconsideration of Crohn's
- Use video library for consistent scoring calibration
- Demonstrate UCEIS scoring within ±1 vs senior before independent practice
2Video Atlas: Crohn's Disease Endoscopy
Videos covering: (1) aphthous ulcers (small, shallow, surrounding erythema); (2) serpiginous/linear ulcers; (3) deep/fissuring ulcers; (4) cobblestone appearance; (5) skip lesions in different segments; (6) strictures (short vs long, inflammatory vs fibrotic); (7) fistula openings; (8) ileocecal valve disease; (9) post-ileocolonic anastomosis appearances across Rutgeerts i0–i4. Rutgeerts score (for 6–12 month post-op ileal assessment): i0 no lesions, i1 ≤5 aphthous lesions, i2 >5 aphthae with normal mucosa between / inflammation confined to anastomosis, i3 diffuse aphthous ileitis, i4 diffuse ileal inflammation with larger ulcers/nodules/narrowing. i2b is refinement: i2a = anastomotic only (favorable), i2b = neoterminal ileum (unfavorable). i3–i4 predicts high recurrence risk—intensify therapy. SES-CD for disease assessment: ulcer size, ulcerated surface %, affected surface %, narrowings; scored in 5 segments (ileum, RC, TC, LC, rectum), total 0–56.
Rutgeerts i2b (neoterminal ileum) is now recognized as a meaningful predictor of clinical recurrence—treat it as i3 for management purposes (intensify therapy). Many older reports combine i2a and i2b; specify the distinction in your report for accurate risk assessment.
- Spectrum: aphthous → serpiginous → cobblestone → stricture/fistula
- Rutgeerts i0–i4; distinguish i2a (favorable) vs i2b (unfavorable)
- SES-CD: 5 segments × 4 parameters (ulcer size, %ulcerated, %affected, stricture)
- i3–i4 post-op predicts high recurrence — intensify therapy
- Document skip lesions, backwash ileitis, ileocecal valve features
3Structured Reporting Templates
A fellowship-grade IBD endoscopy report should include: (1) Indication (surveillance year X from symptom onset / active disease assessment / therapy response); (2) bowel prep quality (Boston BBPS); (3) extent reached; (4) Mayo/UCEIS (UC) or SES-CD/Rutgeerts (CD) with segment-by-segment numerical scoring; (5) lesion inventory with Paris/NICE/JNET classification, size, location (distance from anus for rectum/sigmoid, anatomic landmark otherwise), and management (biopsy/resection/tattoo); (6) biopsy protocol: targeted biopsies detailed separately from random, with numbered jar correspondence; (7) photos embedded or referenced; (8) complications; (9) recommendations: next surveillance interval, medication adjustments, imaging, and MDT referral. Saudi MOH electronic medical records increasingly support structured endoscopy modules; advocate for IBD-specific templates. Reporting in a structured template improves completeness, supports registry data extraction (e.g., Saudi IBD Registry / OASIS), and facilitates MDT discussions.
A structured report is also a teaching tool for the referring clinician. If Mayo 2 in sigmoid and Mayo 0 in transverse, spell it out—"Mayo 2 sigmoid, Mayo 0 transverse" is more actionable than "mild-moderate disease." Use bullet format with numeric scores prominently displayed.
- Standard elements: indication, BBPS, extent, scores, lesions, biopsies, photos, plan
- Segment-by-segment Mayo/UCEIS or SES-CD for accuracy
- SCENIC terminology for dysplasia (visible/invisible, Paris, NICE/JNET)
- Numbered biopsy jars with targeted vs random distinction
- Enable registry extraction via structured fields (Saudi IBD Registry)
- Master Mayo/UCEIS and SES-CD/Rutgeerts scoring via video calibration
- Distinguish Rutgeerts i2a (favorable) from i2b (unfavorable) in post-op ileum
- Structured reports improve completeness and support Saudi IBD Registry
- Use SCENIC terminology; photograph all significant lesions
- Segment-by-segment scoring informs targeted therapy escalation
Assessment
Direct observation of procedural skills (DOPS) in chromoendoscopy + Dysplasia case portfolio
Clinical Pearls
SCENIC recommends chromoendoscopy over standard white-light for dysplasia surveillance
Surveillance starts 8 years after UC diagnosis — earlier if PSC coexists
Balloon dilation safe for Crohn's strictures <4 cm — success 80%, recurrence ~40% at 5 years
Rutgeerts ≥i2 at 6-12 months post-resection predicts clinical recurrence
Pouchitis responds to antibiotics in 80% — refractory pouchitis may be Crohn's of the pouch
Practice Points
Build a chromoendoscopy logbook — document technique, lesion characteristics, histology
Practice NICE classification for polyp characterization during surveillance
For post-surgical CD patients: schedule ileoscopy at 6-12 months for Rutgeerts scoring
Key References
Laine L, et al. SCENIC Consensus on Surveillance and Management of Dysplasia in IBD. Gastroenterology. 2015;148:639-651
Navaneethan U, et al. ASGE guideline on endoscopy in IBD. Gastrointest Endosc. 2015;81:1041-1065
Rutgeerts P, et al. Predictability of postoperative recurrence. Gastroenterology. 1990;99:956-963
Reading List
Chromoendoscopy for IBD dysplasia surveillance
Soetikno R, et al. — Gastrointest Endosc (2012)
SCENIC consensus on dysplasia management
Laine L, et al. — Gastroenterology (2015)
Endoscopic balloon dilation in Crohn's strictures
Bettenworth D, et al. — Aliment Pharmacol Ther (2014)
Pouchoscopy: technique and clinical applications
Shen B, et al. — Inflamm Bowel Dis (2007)